Intermittent levosimendan improves mid-term survival in chronic heart failure patients: Meta-analysis of randomised trials

Simona Silvetti, Teresa Greco, Ambra Licia Di Prima, Marta Mucchetti, Castro Maria De Lurdes, Laura Pasin, Mara Scandroglio, Giovanni Landoni, Alberto Zangrillo

Research output: Contribution to journalArticle

Abstract

Aims: Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. Methods and results: Four investigators independently searched in CENTRAL, Google Scholar MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials to identify any randomized study ever performed with intermittent levosimendan intravenous administration in adult patients with chronic heart failure with no restrictions on dose or time of administration. Data from a total of 326 patients from six randomized controlled studies using intermittent levosimendan in a cardiological setting were included in the analysis. Levosimendan was associated with a significant reduction in mortality at the longest follow-up available [32 of 168 (19 %) in the levosimendan group 46 of 133 (35 %) in the control arm, RR = 0.55 (95 % CI 0.37-0.84), p for effect = 0 0.005, p for heterogeneity = 0.3, I 2 = 23.4 %, NNT = 6 with 5 studies included]. Brain natriuretic peptide values, ejection fraction and number of patients with New York Heart Association ≥III status were similar in survivors of both groups. Conclusions: A large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalClinical Research in Cardiology
Volume103
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Meta-Analysis
Heart Failure
Survival
Brain Natriuretic Peptide
PubMed
MEDLINE
Intravenous Administration
Survivors
simendan
Randomized Controlled Trials
Research Personnel
Clinical Trials
Mortality
Therapeutics

Keywords

  • Chronic heart failure
  • Intermittent administration
  • Levosimendan
  • Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Intermittent levosimendan improves mid-term survival in chronic heart failure patients : Meta-analysis of randomised trials. / Silvetti, Simona; Greco, Teresa; Di Prima, Ambra Licia; Mucchetti, Marta; De Lurdes, Castro Maria; Pasin, Laura; Scandroglio, Mara; Landoni, Giovanni; Zangrillo, Alberto.

In: Clinical Research in Cardiology, Vol. 103, No. 7, 2014, p. 505-513.

Research output: Contribution to journalArticle

Silvetti, Simona ; Greco, Teresa ; Di Prima, Ambra Licia ; Mucchetti, Marta ; De Lurdes, Castro Maria ; Pasin, Laura ; Scandroglio, Mara ; Landoni, Giovanni ; Zangrillo, Alberto. / Intermittent levosimendan improves mid-term survival in chronic heart failure patients : Meta-analysis of randomised trials. In: Clinical Research in Cardiology. 2014 ; Vol. 103, No. 7. pp. 505-513.
@article{3f43e8301c6e411e95a413ab4b6e15c0,
title = "Intermittent levosimendan improves mid-term survival in chronic heart failure patients: Meta-analysis of randomised trials",
abstract = "Aims: Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. Methods and results: Four investigators independently searched in CENTRAL, Google Scholar MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials to identify any randomized study ever performed with intermittent levosimendan intravenous administration in adult patients with chronic heart failure with no restrictions on dose or time of administration. Data from a total of 326 patients from six randomized controlled studies using intermittent levosimendan in a cardiological setting were included in the analysis. Levosimendan was associated with a significant reduction in mortality at the longest follow-up available [32 of 168 (19 {\%}) in the levosimendan group 46 of 133 (35 {\%}) in the control arm, RR = 0.55 (95 {\%} CI 0.37-0.84), p for effect = 0 0.005, p for heterogeneity = 0.3, I 2 = 23.4 {\%}, NNT = 6 with 5 studies included]. Brain natriuretic peptide values, ejection fraction and number of patients with New York Heart Association ≥III status were similar in survivors of both groups. Conclusions: A large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.",
keywords = "Chronic heart failure, Intermittent administration, Levosimendan, Survival",
author = "Simona Silvetti and Teresa Greco and {Di Prima}, {Ambra Licia} and Marta Mucchetti and {De Lurdes}, {Castro Maria} and Laura Pasin and Mara Scandroglio and Giovanni Landoni and Alberto Zangrillo",
year = "2014",
doi = "10.1007/s00392-013-0649-z",
language = "English",
volume = "103",
pages = "505--513",
journal = "Clinical Research in Cardiology",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "7",

}

TY - JOUR

T1 - Intermittent levosimendan improves mid-term survival in chronic heart failure patients

T2 - Meta-analysis of randomised trials

AU - Silvetti, Simona

AU - Greco, Teresa

AU - Di Prima, Ambra Licia

AU - Mucchetti, Marta

AU - De Lurdes, Castro Maria

AU - Pasin, Laura

AU - Scandroglio, Mara

AU - Landoni, Giovanni

AU - Zangrillo, Alberto

PY - 2014

Y1 - 2014

N2 - Aims: Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. Methods and results: Four investigators independently searched in CENTRAL, Google Scholar MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials to identify any randomized study ever performed with intermittent levosimendan intravenous administration in adult patients with chronic heart failure with no restrictions on dose or time of administration. Data from a total of 326 patients from six randomized controlled studies using intermittent levosimendan in a cardiological setting were included in the analysis. Levosimendan was associated with a significant reduction in mortality at the longest follow-up available [32 of 168 (19 %) in the levosimendan group 46 of 133 (35 %) in the control arm, RR = 0.55 (95 % CI 0.37-0.84), p for effect = 0 0.005, p for heterogeneity = 0.3, I 2 = 23.4 %, NNT = 6 with 5 studies included]. Brain natriuretic peptide values, ejection fraction and number of patients with New York Heart Association ≥III status were similar in survivors of both groups. Conclusions: A large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.

AB - Aims: Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. Methods and results: Four investigators independently searched in CENTRAL, Google Scholar MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials to identify any randomized study ever performed with intermittent levosimendan intravenous administration in adult patients with chronic heart failure with no restrictions on dose or time of administration. Data from a total of 326 patients from six randomized controlled studies using intermittent levosimendan in a cardiological setting were included in the analysis. Levosimendan was associated with a significant reduction in mortality at the longest follow-up available [32 of 168 (19 %) in the levosimendan group 46 of 133 (35 %) in the control arm, RR = 0.55 (95 % CI 0.37-0.84), p for effect = 0 0.005, p for heterogeneity = 0.3, I 2 = 23.4 %, NNT = 6 with 5 studies included]. Brain natriuretic peptide values, ejection fraction and number of patients with New York Heart Association ≥III status were similar in survivors of both groups. Conclusions: A large randomized trial is necessary to confirm the promising beneficial effects of intermittent levosimendan administration on the mid-term survival of patients with chronic heart failure.

KW - Chronic heart failure

KW - Intermittent administration

KW - Levosimendan

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84902796549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902796549&partnerID=8YFLogxK

U2 - 10.1007/s00392-013-0649-z

DO - 10.1007/s00392-013-0649-z

M3 - Article

C2 - 24368740

AN - SCOPUS:84902796549

VL - 103

SP - 505

EP - 513

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

SN - 1861-0684

IS - 7

ER -